Trogenix Raises $95M Series A to Accelerate Glioblastoma Clinical Trials

Trogenix, a Scottish biotech company spun out from the University of Edinburgh, has raised £70 million ($95 million) in a Series A financing round led by IQ Capital and backed by investors including Eli Lilly, 4BIO Capital, and Cancer Research Horizons. The funding will accelerate the development of Trogenix's innovative "Trojan horse" cancer therapy platform, Odysseus, which uses synthetic super enhancers delivered via viral vectors to selectively target and kill cancer cells while stimulating an immune response. Their lead program focuses on glioblastoma, a highly aggressive brain cancer, with plans to begin clinical trials and first patient dosing in early 2026. The investment will also support advancing follow-on programs targeting colorectal cancer liver metastases, liver, and lung cancers. Trogenix aims to deliver curative, precision therapies for treatment-resistant solid tumors by combining cancer cell killing with immune memory activation, reflecting strong investor confidence in its scientific and commercial potential. This round is among the largest early-stage biotech financings in Europe in 2025, underscoring sustained investor enthusiasm for innovative oncology platforms.